Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Faeth Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 25.84M shares outstanding
USFaeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Leadership
Christopher Gerry
General Counsel & Secretary
Josiah Craver
Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer
Anand Parikh
CEO, President & Chair
Benjamin Hopkins
Scientific Co-Founder
Employees
--
Country
US
Sector
Healthcare
Website
faeththerapeutics.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Vousden Karen H | Director | Grant/Award | 25.0K | -- | Sep 11, 2026 |
 Parikh Anand Kiran | President and CEO | Grant/Award | 398.0K | -- | Jul 21, 2026 |
 Craver Josiah | PAO | Grant/Award | 30.8K | -- | Jul 21, 2026 |
 STEPHENSON BRIAN C | Chief Financial Officer | Purchase | 4.4K | $103.0K | Jul 1, 2026 |
| STEPHENSON BRIAN C | Chief Financial Officer | Purchase | 600 | $14.5K | Jul 1, 2026 |
| STEPHENSON BRIAN C | Chief Financial Officer | Purchase | 1.9K | $43.8K | Jun 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
MONTANOVA CAPITAL, LLC | 2.0M | 7.8% | 13F |
Avoro Capital Advisors LLC | 1.4M | 5.6% | 13F |
BAKER BROS. ADVISORS LP | 1.3M | 5.0% | 13F |
BALYASNY ASSET MANAGEMENT L.P. | 1.0M | 4.0% | 13F |
Cormorant Asset Management, LP | 1.0M | 4.0% | 13F |
 Parikh Anand Kiran President and CEO, Director | 817.7K | 3.2% | FORM 4 |
Fairmount Funds Management LLC | 722.0K | 2.8% | 13F |
Logos Global Management LP | 722.0K | 2.8% | 13F |
RA CAPITAL MANAGEMENT, L.P. | 722.0K | 2.8% | 13F |
Vivo Capital, LLC | 722.0K | 2.8% | 13F |
Insiders
- Vousden Karen HDirector
- Parikh Anand KiranPresident and CEO
- Craver JosiahPAO
- STEPHENSON BRIAN CChief Financial Officer
- Hahn Stephen M.Director
- Ramasastry SairaDirector
- Cambrian BioPharma Inc10% Owner
- Peyer James10% Owner
- Celebi JohnPRESIDENT AND CEO, Director
- van der Horst EdwardCHIEF SCIENTIFIC OFFICER
based on 25.84M shares outstanding
US30d Avg
337.21K
60d Avg
389.86K
90d Avg
360.47K